Picard Medical (PMI)


Market Price (11/21/2026): $6.78 | Market Cap: $18.0 MilSector: Health Care | Industry: Life Sciences Tools & Services

Picard Medical (PMI)


Market Price (11/21/2026): $6.78
Market Cap: $18.0 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, Precision Medicine, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, Show more.

Weak multi-year price returns
2Y Excs Rtn is -123%, 3Y Excs Rtn is -162%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -14 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -267%

Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -82%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 35%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -216%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -217%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -130%

High stock price volatility
Vol 12M is 224%

Key risks
PMI key risks include [1] its precarious financial health and a stated "going concern" risk, Show more.

0 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, Precision Medicine, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, Show more.
1 Weak multi-year price returns
2Y Excs Rtn is -123%, 3Y Excs Rtn is -162%
2 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -14 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -267%
3 Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -82%
4 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 35%
5 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -216%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -217%
6 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -130%
7 High stock price volatility
Vol 12M is 224%
8 Key risks
PMI key risks include [1] its precarious financial health and a stated "going concern" risk, Show more.

PMI in ETFs

Weight = PMI's share of each fund

VTI0.00%

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/20/2026

Nov 20: up 7.8% in one day (S&P 500 down 3.6%)
The stock gained without company news. The broader market declined on this day.

Down 30.0% from its Nov 6 high to Nov 19, up 7.8% since (S&P 500 down 2.6%)
The stock declined over this period without company news, as did the broader market by a much smaller amount. This trend included drops on November 9, November 13, and November 18.

Show more
Prices as of 11/20/2026

Nov 20: up 7.8% in one day (S&P 500 down 3.6%)
The stock gained without company news. The broader market declined on this day.

Down 30.0% from its Nov 6 high to Nov 19, up 7.8% since (S&P 500 down 2.6%)
The stock declined over this period without company news, as did the broader market by a much smaller amount. This trend included drops on November 9, November 13, and November 18.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 54.5% change in PMI stock from 7/31/2026 to 11/20/2026 was primarily driven by a 149.9% change in the company's P/S Multiple.
(LTM values as of)731202611202026Change
Stock Price ($)4.396.7954.5%
Change Contribution By: 
Total Revenues ($ Mil)55-2.7%
P/S Multiple1.23.0149.9%
Shares Outstanding (Mil)12-36.5%
Cumulative Contribution54.5%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/20/2026
ReturnCorrelation
PMI54.5% 
Market (SPY)-7.4%-1.5%
Sector (XLV)9.5%-12.7%

Fundamental Drivers

The -70.2% change in PMI stock from 4/30/2026 to 11/20/2026 was primarily driven by a -56.0% change in the company's P/S Multiple.
(LTM values as of)430202611202026Change
Stock Price ($)22.756.79-70.2%
Change Contribution By: 
Total Revenues ($ Mil)557.7%
P/S Multiple6.83.0-56.0%
Shares Outstanding (Mil)12-37.1%
Cumulative Contribution-70.2%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/20/2026
ReturnCorrelation
PMI-70.2% 
Market (SPY)-3.5%4.8%
Sector (XLV)22.4%-9.3%

Fundamental Drivers

The -95.1% change in PMI stock from 10/31/2025 to 11/20/2026 was primarily driven by a -93.3% change in the company's P/S Multiple.
(LTM values as of)1031202511202026Change
Stock Price ($)137.506.79-95.1%
Change Contribution By: 
Total Revenues ($ Mil)4519.3%
P/S Multiple44.53.0-93.3%
Shares Outstanding (Mil)12-38.3%
Cumulative Contribution-95.1%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/20/2026
ReturnCorrelation
PMI-95.1% 
Market (SPY)2.2%5.4%
Sector (XLV)24.9%-4.7%

Fundamental Drivers

null
null

Market Drivers

10/31/2023 to 11/20/2026
ReturnCorrelation
PMI  
Market (SPY)71.0%3.9%
Sector (XLV)49.6%-2.7%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
PMI Return-----62%-92%-97%
Peers Return21%-21%7%10%22%3%40%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
PMI Win Rate----20%27% 
Peers Win Rate58%43%50%58%62%49% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
PMI Max Drawdown------97% 
Peers Max Drawdown-17%-34%-25%-18%-16%-26% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: JNJ, ABT, MDT, EW, ISRG.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/20/2026 (YTD)

How Low Can It Go

PMI has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2025 US Tariff Shock
  % Loss-11.7%-18.8%
  % Gain to Breakeven13.3%23.1%
  Time to Breakeven142 days79 days
2022 Inflation Shock & Fed Tightening
  % Loss-13.8%-24.5%
  % Gain to Breakeven15.9%32.4%
  Time to Breakeven166 days427 days
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-15.0%-19.2%
  % Gain to Breakeven17.6%23.8%
  Time to Breakeven191 days105 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-15.9%-12.2%
  % Gain to Breakeven18.9%13.9%
  Time to Breakeven165 days62 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-15.8%-17.9%
  % Gain to Breakeven18.8%21.8%
  Time to Breakeven153 days123 days

Compare to JNJ, ABT, MDT, EW, ISRG

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

PMI has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
2008-2009 Global Financial Crisis
  % Loss-37.9%-53.4%
  % Gain to Breakeven61.1%114.4%
  Time to Breakeven767 days1085 days

Compare to JNJ, ABT, MDT, EW, ISRG

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Picard Medical (PMI)

N/A

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

Patrick NJ Schnegelsberg Chief Executive Officer

Patrick NJ Schnegelsberg, 61, has served as Chief Executive Officer of Picard Medical, Inc. (PMI) and its wholly owned subsidiary SynCardia Systems LLC since July 5, 2023. He has over 25 years of executive leadership experience in the medical device industry. Before joining PMI, he was CEO of Syntach AB from December 2022 to July 2023 and held COO and CEO roles with the Occlutech Group and its subsidiaries from 2012 to 2021. Mr. Schnegelsberg has also held C-level positions with several European and U.S. medtech and biotech start-ups. He previously held director-level roles on Wall Street, conducted research at MIT, and is a graduate of Harvard Medical School and Clark University. He currently serves on the board of Acorai AB and is a former board member of Scandinavian Real Heart. In December 2025, he was elected to the Board of Directors of the Arizona Bioindustry Association (AZBio).

Bernard Skaggs Chief Financial Officer

Bernard Skaggs was appointed Chief Financial Officer of Picard Medical, Inc. (PMI) and SynCardia in November 2023. He brings over 30 years of experience in finance and accounting to the role. His career includes serving as Controller at Golden Vertex Corporation, Plant Controller at Asarco LLC, Controller Consultant at Experis, Plant Controller at Embraer Aero Seating Technologies, Accounting Manager at Cancer Prevention Pharmaceuticals, and various positions at Deloitte. Mr. Skaggs holds a BA from the University of Arizona, an MAcc from the University of Phoenix, and an MBA from Thunderbird. He is also a U.S. Army veteran.

Matthew Schuster Chief Operating Officer

Matthew Schuster serves as the Chief Operating Officer of Picard Medical, Inc.

AI Analysis | Feedback

The key risks for Picard Medical (symbol: PMI) are primarily centered around ongoing legal issues, financial instability, and product-specific challenges in the highly regulated medical device market.

  1. Securities Fraud and Stock Manipulation Lawsuit: Picard Medical is currently facing multiple class-action lawsuits alleging a fraudulent stock promotion scheme. These lawsuits claim that the company was involved in social media-based misinformation, the use of impersonated financial professionals, and that insiders or affiliates utilized offshore accounts to facilitate coordinated share dumping during a price inflation campaign. This alleged scheme led to a significant crash in Picard Medical's stock price.
  2. Financial Distress and Shareholder Dilution: The company exhibits signs of significant financial instability, including a falling stock price, declining annual total revenue, and increasing net losses from 2023 to 2024. Furthermore, Picard Medical has a negative price-to-book ratio, indicating that its liabilities exceed its assets. Investor confidence has been further eroded by concerns over potential shareholder dilution following an expanded equity incentive plan.
  3. High Reliance on a Single Product and Regulatory Environment: Picard Medical's business is heavily concentrated on the development, manufacturing, and commercialization of its implantable Total Artificial Heart (TAH), particularly the SynCardia TAH. While the SynCardia TAH is FDA and Health Canada approved, the company's significant reliance on this single core product exposes it to considerable risks should there be adverse developments related to its performance, regulatory changes, or increased competition within the highly specialized medical device industry.

AI Analysis | Feedback

null

AI Analysis | Feedback

Picard Medical (PMI) Addressable Markets

Picard Medical (PMI) operates primarily in the Total Artificial Heart (TAH) market, manufacturing and commercializing the SynCardia TAH, an implantable system designed to assume the full function of a failed human heart in patients with advanced heart failure, serving as a bridge to heart transplantation.

The global addressable market for Total Artificial Hearts was valued at approximately USD 52.6 million in 2024 and is projected to grow to USD 223 million by 2032, exhibiting a Compound Annual Growth Rate (CAGR) of 23.5% during the forecast period. Another estimate places the global market at USD 132.68 million in 2025, with a projected increase to USD 435.85 million by 2032, growing at a CAGR of 18.5%. SynCardia, a subsidiary of Picard Medical, holds a near-total market share for commercially available, FDA-approved Total Artificial Hearts used as a bridge-to-transplantation.

AI Analysis | Feedback

Here are 3-5 expected drivers of future revenue growth for Picard Medical (symbol: PMI) over the next 2-3 years:

  1. Increased Sales and Rental Income of the SynCardia Total Artificial Heart (TAH): Picard Medical has reported strong sales growth for its SynCardia TAH, which is currently the only commercially available total artificial heart approved in the U.S. and Canada. The company's recent earnings reports highlight a significant increase in revenues, driven by both product sales and rental income, indicating continued growth from its flagship product.
  2. Global Market Expansion of the SynCardia Platform: The company's strategy includes efforts to expand the availability and access of its SynCardia platform in international markets. This global expansion aims to enhance Picard Medical's competitive positioning in the medical devices industry.
  3. Development and Commercialization of the Next-Generation Artificial Heart Platform (Emperor): Picard Medical is actively investing in and progressing with its next-generation, fully implantable total artificial heart platform, known as "Emperor." The capital raised from its recent initial public offering (IPO) is specifically intended to advance the development and eventual commercialization of this new product, which is a key future growth driver.

AI Analysis | Feedback

Capital Allocation Decisions (2021-2025) for Picard Medical (PMI)

Share Issuance

  • Picard Medical completed its Initial Public Offering (IPO) on August 29, 2025, raising $17 million in gross proceeds from the sale of 4,250,000 shares at $4.00 per share.
  • Underwriters fully exercised their over-allotment option on September 5, 2025, resulting in the issuance of an additional 637,500 shares at $4.00 per share, generating $2.55 million in gross proceeds.
  • In October 2025, stockholders approved an amendment to the 2021 Equity Incentive Plan, increasing the total shares available under the plan to 18,000,000 and adding warrants as an award type for future potential issuance.

Inbound Investments

  • In September 2021, Hunniwell, through its majority-held investment vehicle Picard Medical, Inc., purchased 85% of the ownership interest in SynCardia Systems, LLC.
  • Picard Medical entered into a definitive agreement in December 2025 for a private placement financing of up to $50.0 million in senior secured notes due 2028, along with warrants to purchase common stock, with an initial issuance of $15 million.

Outbound Investments

  • In July 2023, Picard Medical, Inc. agreed to acquire a majority ownership of SynCardia Medical (Beijing) Inc., a company responsible for the registration, sale, and distribution of the SynCardia Total Artificial Heart (TAH) in China, contingent on Picard Medical becoming publicly traded.

Capital Expenditures

  • While no specific dollar values for capital expenditures were publicly detailed, research and development is identified as an area requiring high capital expenditure for the company.

Peer Outperformance in Life Sciences Tools & Services

PMI has trailed 89% of its 125 Life Sciences Tools & Services peers over 1Y. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Life Sciences Tools & Services constituents that PMI has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
11%
of 125 industry peers · -93.8% return
3Y
—
insufficient price history
5Y
—
insufficient price history
No Life Sciences Tools & Services peer with a comparable growth profile has beaten PMI by more than 20pp over 1Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is PMI's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 17.3%74.7%198.5% CAH 523% · MCK 396% · COR 198%
Health Care Services 20 30.7%20.5%14.0% RDNT 146% · HIMS 100% · DGX 92%
Managed Health Care 8 60.1%-12.7%-9.2% OSCR 140% · HQY 54% · ELV 2%
Health Care Facilities 26 13.2%13.0%-10.4% THC 240% · NHC 211% · EHC 187%
Health Care Equipment 50 -2.1%6.7%-19.0% GKOS 393% · UFPT 319% · TMDX 274%
Health Care Supplies 11 19.9%-4.3%-41.8% LNTH 256% · HAE 114% · MMSI 22%
Pharmaceuticals 61 -16.1%-0.2%-42.0% LQDA 1178% · KNSA 670% · XERS 648%
Life Sciences Tools & Services ← 110 -25.7%-28.8%-76.5% AXGN 471% · MEDP 169% · NTRA 165%
Biotechnology 370 -35.9%-45.4%-85.2% ELVN 1310% · DNTH 1164% · TRVI 1159%
Health Care Technology 23 -26.4%-56.9%-86.5% VEEV -13% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

PMIJNJABTMDTEWISRGMedian
NamePicard M.Johnson .Abbott L.MedtronicEdwards .Intuitiv. 
Mkt Price6.78270.55103.31100.00101.86400.06102.58
Mkt Cap0.0651.9179.2128.058.7139.6133.8
Rev LTM599,33548,22937,5416,67511,57824,560
Op Inc LTM-1425,5256,6477,1471,9223,7345,191
FCF LTM-1219,5956,7576,1321,4243,5984,865
FCF 3Y Avg-1319,1006,7205,5279052,1523,839
CFO LTM-1226,1598,8558,0351,7174,0906,062
CFO 3Y Avg-1325,1708,9017,3601,1802,9575,158

Growth & Margins

PMIJNJABTMDTEWISRGMedian
NamePicard M.Johnson .Abbott L.MedtronicEdwards .Intuitiv. 
Rev Chg LTM11.6%7.8%10.0%9.8%13.4%20.5%10.8%
Rev Chg 3Y Avg-5.9%6.5%6.0%14.7%19.2%6.5%
Rev Chg Q-81.7%5.9%14.5%13.7%10.5%21.7%12.1%
QoQ Delta Rev Chg LTM-15.4%1.4%3.5%3.2%2.5%4.9%2.9%
Op Inc Chg LTM-3.0%7.9%-13.8%7.5%18.7%32.6%7.7%
Op Inc Chg 3Y Avg-4.4%4.3%6.3%11.7%30.4%6.3%
Op Mgn LTM-267.2%25.7%13.8%19.0%28.8%32.3%22.4%
Op Mgn 3Y Avg-307.7%25.4%15.9%18.5%28.1%29.3%22.0%
QoQ Delta Op Mgn LTM-19.1%-1.1%-2.0%0.3%0.7%1.0%-0.4%
CFO/Rev LTM-216.2%26.3%18.4%21.4%25.7%35.3%23.6%
CFO/Rev 3Y Avg-268.7%27.1%20.1%21.2%19.4%29.8%20.6%
FCF/Rev LTM-216.7%19.7%14.0%16.3%21.3%31.1%18.0%
FCF/Rev 3Y Avg-268.9%20.6%15.2%15.9%14.7%20.7%15.5%

Valuation

PMIJNJABTMDTEWISRGMedian
NamePicard M.Johnson .Abbott L.MedtronicEdwards .Intuitiv. 
Mkt Cap0.0651.9179.2128.058.7139.6133.8
P/S3.06.63.73.48.812.15.1
P/Op Inc-1.125.527.017.930.537.426.2
P/EBIT-0.834.823.717.537.237.429.3
P/E-0.840.538.124.557.547.239.3
P/CFO-1.424.920.215.934.234.122.6
Total Yield-124.4%4.4%5.1%6.9%1.7%2.1%3.3%
Dividend Yield0.0%2.0%2.4%2.9%0.0%0.0%1.0%
FCF Yield 3Y Avg-4.0%3.4%5.3%2.0%1.4%3.4%
D/E0.20.10.20.20.00.00.1
Net D/E0.20.00.10.2-0.1-0.00.1

Returns

PMIJNJABTMDTEWISRGMedian
NamePicard M.Johnson .Abbott L.MedtronicEdwards .Intuitiv. 
1M Rtn-29.6%5.0%2.8%7.5%15.2%-6.6%3.9%
3M Rtn111.2%0.6%-10.9%8.0%13.4%5.6%6.8%
6M Rtn-10.2%16.7%19.8%29.4%18.7%-8.7%17.7%
12M Rtn-93.8%36.2%-14.6%4.0%21.1%-27.6%-5.3%
3Y Rtn-97.0%93.4%8.0%40.3%52.1%28.3%34.3%
1M Excs Rtn-4.8%4.3%4.0%6.8%16.3%-6.6%4.2%
3M Excs Rtn35.2%2.7%-7.8%11.6%15.6%10.2%10.9%
6M Excs Rtn-9.4%17.4%20.5%30.2%19.5%-7.9%18.5%
12M Excs Rtn-105.9%24.9%-27.8%-8.7%6.8%-40.8%-18.2%
3Y Excs Rtn-161.7%33.3%-52.6%-15.7%-12.7%-28.4%-22.1%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil2025202420232022
Products5454
Rentals0000
Total5454


Price Behavior

Price Behavior
Market Price$6.79 
Market Cap ($ Bil)0.0 
First Trading Date10/31/2013 
Distance from 52W High-96.3% 
   50 Days200 Days
DMA Price$7.65$21.30
DMA Trendupdown
Distance from DMA-11.3%-68.1%
 3M1YR
Volatility289.5%223.7%
Downside Capture-139.25405.48
Upside Capture278.2431.30
Correlation (S&P 500)2.0%5.9%
PMI Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta4.272.58174.4067.8831.57-1.97
Up Beta49.32-5.43571.21204.9481.6424.41
Down Beta15.4810.4710.769.013.89-1.27
Up Capture391%150%32693%12267%3286%145%
Bmk +ve Days12182862130427
Stock +ve Days1424335395120
Down Capture-919%136%52%232%183%104%
Bmk -ve Days10253664121325
Stock -ve Days8183061141155

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with PMI
PMI-95.2%226.7%-0.35-
Sector ETF (XLV)18.4%17.1%0.80-4.4%
Equity (SPY)5.2%14.4%0.114.3%
Gold (GLD)-13.9%29.3%-0.525.6%
Commodities (DBC)28.2%21.5%1.05-6.8%
Real Estate (VNQ)8.6%14.3%0.33-6.0%
Bitcoin (BTCUSD)-32.4%43.7%-0.78-3.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with PMI
PMI-52.1%216.9%-0.38-
Sector ETF (XLV)7.5%15.4%0.29-2.6%
Equity (SPY)9.6%17.4%0.393.3%
Gold (GLD)13.1%19.3%0.537.2%
Commodities (DBC)6.6%19.6%0.22-5.1%
Real Estate (VNQ)0.5%19.0%-0.08-2.6%
Bitcoin (BTCUSD)-0.7%51.4%0.17-2.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with PMI
PMI-30.8%216.9%-0.38-
Sector ETF (XLV)11.4%16.8%0.55-2.6%
Equity (SPY)14.1%18.1%0.663.3%
Gold (GLD)10.4%16.6%0.507.2%
Commodities (DBC)7.2%18.2%0.31-5.1%
Real Estate (VNQ)5.9%20.7%0.24-2.6%
Bitcoin (BTCUSD)56.2%66.3%0.96-2.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity0.1 Mil
Short Interest: % Change Since 1015202644.9%
Average Daily Volume0.4 Mil
Days-to-Cover Short Interest1
Basic Shares Quantity2.3 Mil
Short % of Basic Shares3.2%

Earnings Returns History

Updated 11/3/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/21/20267.1%4.6%23.7%
3/25/20263.0%5.1%-14.8%
11/14/2025-3.7%-15.9%-17.4%
SUMMARY STATS   
# Positive221
# Negative112
Median Positive5.1%4.8%23.7%
Median Negative-3.7%-15.9%-16.1%
Max Positive7.1%5.1%23.7%
Max Negative-3.7%-15.9%-17.4%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/21/20267.1%4.6%23.7%
3/25/20263.0%5.1%-14.8%
11/14/2025-3.7%-15.9%-17.4%
SUMMARY STATS   
# Positive221
# Negative112
Median Positive5.1%4.8%23.7%
Median Negative-3.7%-15.9%-16.1%
Max Positive7.1%5.1%23.7%
Max Negative-3.7%-15.9%-17.4%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/16/202610-Q
06/30/202608/19/202610-Q
03/31/202605/15/202610-Q
12/31/202503/30/202610-K
09/30/202511/14/202510-Q
06/30/202509/12/202510-Q
03/31/202509/02/2025424B4
09/30/202401/24/2025DRS/A
06/30/202411/12/2024DRS/A
03/31/202408/23/2024DRS
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/16/202610-Q
06/30/202608/19/202610-Q
03/31/202605/15/202610-Q
12/31/202503/30/202610-K
09/30/202511/14/202510-Q
06/30/202509/12/202510-Q
03/31/202509/02/2025424B4
09/30/202401/24/2025DRS/A
06/30/202411/12/2024DRS/A
03/31/202408/23/2024DRS
Core Cache Last Updated: 11/20/2026